As a leading and proven OEM processor of high quality placental tissue biologics we are thrilled to be providing turn-key solutions for companies looking to add an innovative FastActing™ amniotic membrane
El Segundo, CA (PRWEB)
April 10, 2017
This suturable BioECM becomes the third in HRT’s membrane offering, designed to give surgeons additional handling options to solve the unique application needs of various procedures.
This new product launch continues to add to the milestones achieved in 2017, where the Centers for Medicare & Medicaid Services approved HRT’s FastActing® membrane skin substitute for high-cost bundle payment status under its unique HCPCS code Q4163. This status allows for enhanced reimbursement at hospital outpatient and hospital-affiliated ambulatory facilities, expanding patient access to this next-generation biologic.
“As a company, our mission is to create the most viable biologic solutions, so patients have the best opportunity for a successful outcome, as shown in our previous wound study with our proprietary FastActing™ membranes,” said Chris Sharp CEO, Skye Biologics. “ As a leading and proven OEM processor of high quality amniotic and placental tissue biologics we are thrilled to be providing numerous turn-key solution for those companies looking to add an innovative FastActing™ amniotic membrane product line up for surgical applications or advanced wound care.”
“We are committed to developing new, innovative product formulations to meet the various needs of physicians and the patients they treat. We pride ourselves on our HydraTek Process and how well we preserve the biologic integrity of these tissues. Historically this has not been a consideration by many biologic and tissue processors.”
FastActing Amniotic Membranes…